| Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy. | |
| | |
MedLine Citation:
|
PMID: 22235061 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Methylene blue has been used not only as a diagnostic agent, but also as an agent in the treatment of ifosfamide-induced encephalopathy (IIE) for several years. Recently, several cases of suspected serotonin syndrome have been reported in patients who received methylene blue in combination with serotonin active agents. Rodent models have revealed that methylene blue is a potent, reversible inhibitor of monoamine oxidase A. It is well known that serotonin active drugs, in combination with monoamine oxidase inhibitors can produce profound serotonin syndrome. To date, cases of serotonin syndrome, which resulted from concurrent methylene blue and serotonin active agents, have been published in the anesthesia literature. We report the first known case of serotonin syndrome in a patient receiving methylene blue for IIE. |
| | |
Authors:
|
A M McDonnell; I Rybak; M Wadleigh; D C Fisher |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-10 |
Journal Detail:
|
Title: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners Volume: - ISSN: 1477-092X ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-1-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9511372 Medline TA: J Oncol Pharm Pract Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Brigham and Women's Hospital, Boston, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Epilepsy as a Disorder of Cortical Network Organization.
Next Document: Bilateral Wilms' tumor: Mansoura multi-centers 15 years experience.